Test Price
1,500 AED✅ Home Collection Available
JAK2 V617F Reflex to JAK2 Exon 12 Mutation Detection Test in UAE | 1500 AED | 2026 DHA Guidelines
تحليل طفرة جاك 2 في 617إف مع تحليل طفرات إكسون 12 في الإمارات | 1500 درهم | معتمد من هيئة الصحة بدبي
يقدم هذا الفحص التشخيصي الجزيئي المتقدم الكشف الدقيق عن طفرة جاك 2 في الموقع 617إف مع التحليل الانعكاسي لطفرات إكسون 12 باستخدام تقنية تفاعل البوليميراز المتسلسل الكمي والتحليل الجزئي للحمض النووي. يتم تنفيذ هذا الفحص وفقاً لمعايير هيئة الصحة بدبي والمرسوم بقانون اتحادي رقم 41 لسنة 2024، مع ضمان دقة تشخيصية بنسبة 99.9% عبر مختبراتنا المعتمدة دولياً بشهادة الأيزو 9001:2015. هذا التحليل هو المعيار الذهبي لتشخيص الأورام التكاثرية النقوية السلبية لكروموسوم فيلادلفيا.
- ✓ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
- ✓ Premium Logistics: Paid Hospital-Grade Home Collection via ISO-Certified Cold-Chain Home Collection and VIP Mobile Phlebotomy — 8 AM to 11 PM, 7 days a week.
- ✓ Clinical Guidance: Telephonic Post-Test Clinical Guidance for result interpretation with our DHA-licensed clinical team.
- ✓ Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.
Overview: JAK2 Mutation Detection in Myeloproliferative Neoplasms
The JAK2 V617F Reflex to JAK2 Exon 12 Mutation Detection Test is a high-resolution molecular assay designed to identify somatic activating mutations in the Janus Kinase 2 gene — the defining biomarker in over 98% of polycythemia vera cases and a critical diagnostic criterion in essential thrombocythemia and primary myelofibrosis. يكتشف هذا الاختبار الطفرة الجينية الأساسية المسببة للأورام التكاثرية النقوية بدقة تشخيصية عالية. This reflex protocol ensures that if the common V617F mutation is not detected, the sample is automatically tested for rarer Exon 12 mutations, eliminating diagnostic blind spots.
| Parameter | Our Test (Loqman Precision Diagnostics) | Closest Alternative |
|---|---|---|
| Precision | 99.9% Diagnostic Sensitivity — Dual-target qPCR + Fragment Analysis with Exon 12 Reflex | Single-locus V617F genotyping only (~96% sensitivity; misses Exon 12 mutations) |
| Methodology | Real-Time PCR (qPCR) + Fragment & STR Analysis — ISO 9001:2015 validated | Conventional PCR or Sanger sequencing (lower sensitivity; longer TAT) |
| Speed | 5-Day Turnaround — Sample by Mon 11 AM → Report Sat | 7–14 Days (offshore reference labs; cold-chain delays) |
| UAE Compliance | DHA-Licensed (Facility 9834453) — Federal Decree-Law No. 41 of 2024 Compliant | May lack UAE-specific regulatory alignment |
Physician Insight & Safety Protocol
"The JAK2 V617F mutation is present in approximately 96% of polycythemia vera patients and 50–60% of essential thrombocythemia and primary myelofibrosis cases — but a negative V617F result does not exclude disease. That is precisely why this reflex panel extends to Exon 12 mutations, which account for the majority of the remaining PV cases. I cannot overstate the importance of correlating these molecular findings with hemoglobin, hematocrit, platelet counts, and bone marrow biopsy results. A positive JAK2 test alone, in the absence of clinical and morphological correlation, is insufficient to establish a definitive diagnosis of a myeloproliferative neoplasm."
— Dr. Prabhakar Reddy, Consultant Hematopathologist, DHA License: 61713011
⚠ Medication Safety Notice
Do not discontinue prescribed medication without consulting your doctor.
Patients on hydroxyurea, ruxolitinib, interferon-alpha, or aspirin therapy must continue their prescribed regimen unless explicitly advised otherwise by their treating hematologist-oncologist. Abrupt discontinuation can precipitate thrombotic events or disease progression.
Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: This test is not indicated for isolated erythrocytosis of non-clonal origin (e.g., chronic hypoxia, high-altitude adaptation, EPO-secreting tumors, or relative polycythemia due to plasma volume contraction). Confirm secondary causes before ordering.
- ER Red Flag: If you experience sudden severe headache, visual disturbances, intense pruritus after showering (aquagenic pruritus), or signs of thrombosis (unilateral leg swelling, chest pain, dyspnea), seek emergency medical evaluation immediately — these may indicate uncontrolled myeloproliferation requiring urgent intervention.
- Minors: Per UAE CDS Law 2026, this genetic susceptibility test is not routinely indicated for minors without explicit clinical justification and guardian consent documented on Form 20.
Pre- Information & Specimen Requirements
- Specimen: 3 mL (2 mL minimum) whole blood collected in 1 Lavender Top (EDTA) tube.
- Transport: Ship refrigerated. DO NOT FREEZE.
- Mandatory Documentation: Duly filled Genomics Clinical Information Requisition Form (Form 20) is mandatory. Incomplete forms will result in specimen rejection.
- Collection Window: Sample must be received by Monday 11 AM for Saturday reporting.
- Medication Disclosure: Patients must disclose all current medications, including anticoagulants, aspirin, and cytoreductive agents, on Form 20.
- Dietary Status: No fasting required; however, hydration is recommended to facilitate venipuncture.
Patient FAQ & Clinical Guidance
Q1: What does a positive JAK2 V617F mutation result mean for my diagnosis?
A: A positive JAK2 V617F mutation result indicates the presence of an acquired (somatic) genetic variant strongly associated with Philadelphia-negative myeloproliferative neoplasms, most commonly polycythemia vera, and must be interpreted alongside your complete blood count, erythropoietin level, and bone marrow biopsy by your hematologist-oncologist. This result alone is not a cancer diagnosis but a critical piece of the diagnostic puzzle that, when combined with clinical findings, helps guide targeted therapy decisions.
Q2: Why is the Exon 12 reflex testing necessary if my V617F result is negative?
A: Approximately 4% of polycythemia vera patients harbor JAK2 mutations exclusively in Exon 12 rather than the common V617F site, and without reflex testing these patients would receive a false-negative result, leading to diagnostic delay and missed opportunities for early therapeutic intervention. The reflex protocol ensures complete molecular coverage so that no JAK2-driven myeloproliferative neoplasm goes undetected.
س3: هل يمكن إجراء هذا التحليل للمرضى الذين يتناولون أدوية مميعات الدم مثل الأسبرين؟
ج: نعم، يمكن إجراء تحليل طفرة جاك 2 بأمان للمرضى الذين يتناولون الأسبرين أو مميعات الدم الأخرى دون الحاجة إلى التوقف عن تناول الدواء، حيث يتم سحب العينة من الوريد المحيطي باستخدام إجراءات قياسية آمنة مع الضغط الموضعي بعد السحب. يجب إبلاغ فريق التمريض بجميع الأدوية الحالية عند تعبئة نموذج المعلومات السريرية الجينومية (نموذج 20).
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians